FDA Warning Letter
ABC Food Corp
CGMP/Food/Prepared, Packed or Held Under Insanitary Conditions/Adulterated
- 発出日
- 2026.10.05
- 掲載日
- 2026.11.10
- 発行オフィス
- Human Foods Program
- MARCS-CMS 番号
- 730984
- 配達方法
- VIA ELECTRONIC DELIVERY
- 宛先
- Stephanie D. Lin
本文(英語原文)
- Delivery Method:
- VIA ELECTRONIC DELIVERY
- Product:
- Food & Beverages
- Recipient:
-
Recipient NameStephanie D. Lin
-
Recipient TitlePresident/Co-Owner
- ABC Food Corp
99 Atkinson St
Boston, MA 02118-2701
United States- (b)(6), (b)(7)(C)
- Issuing Office:
- Human Foods Program
United States
United States
WARNING LETTER
Re: CMS # 730984
Dear Ms. Lin:
The United States Food and Drug Administration (FDA) inspected your food manufacturing facility located at 99 Atkinson St, Boston, MA 02118-2701, from March 17, 2026 through April 7, 2026. Your firm manufactures ready-to-eat (RTE) rice noodles and RTE tofu. During our inspection, the FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).
Based on FDA’s inspectional findings, we have determined that the RTE rice noodle and tofu products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code, (U.S.C.) § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. Additionally, the failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links on FDA’s homepage at www.fda.gov.
At the conclusion of the inspection, the FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. We received your written response to the FDA-483 on April 28, 2026, describing your planned and implemented corrective actions. Based on our review of the inspectional findings and your response, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility. We discuss your response below.
Hazard Analysis and Risk-Based Preventive Controls (21 CFR part 117, Subpart C):
1. You did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for each type of food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control, as required by 21 CFR 117.130(a)(1). You did not conduct and document a hazard analysis for any of the foods that you manufacture. For example:
A. You did not identify and evaluate the hazard of bacterial pathogen growth and/or toxin formation of Clostridium botulinum (C. botulinum) and Bacillus cereus (B. cereus) due to time/temperature abuse as a hazard requiring a preventive control for your RTE Ho Foon Cut rice noodles.
C. botulinum
Your RTE Ho Foon Cut rice noodle products are packaged and stored in reduced oxygen packaging (ROP). Various ingredients in these products (b)(4) grow in the ground or are associated with soil, where spores of C. botulinum may be present. Your practice of (b)(4) packing the rice noodles into impermeable bags and then squeezing the bags to remove air before tying and sealing produces an anaerobic environment. Therefore, C. botulinum growth and/or toxin formation in ROP is a known or reasonably foreseeable hazard for this product at the cooling and cold storage steps.
B. cereus
B. cereus is a spore-forming bacterium commonly found in soil and raw agricultural commodities, such as rice. While cooking effectively destroys its vegetative cells, the spores are notably heat-resistant and can survive standard cooking processes. Therefore, B. cereus growth and/or toxin formation is a known or reasonably foreseeable hazard for this product at the cooling and cold storage steps.
You do not formulate your products (e.g., by decreasing pH or water activity) to prevent pathogen growth and/or toxin formation. Also, your (b)(4) process (observed during the inspection as approximately (b)(4) thermometer set at (b)(4) is not adequate to destroy spore-forming bacteria. If your rice noodles are time/temperature abused, bacterial spores (such as C. botulinum and B. cereus) could germinate into vegetative cells, grow, and form toxins that may lead to foodborne illness. Therefore, a knowledgeable person manufacturing/processing food in your circumstances would identify bacterial growth and/or toxin formation by spore-formers due to time/temperature abuse as a hazard requiring a preventive control at the cooling and cold storage steps.
Your facility has not established preventive controls, such as process controls, for these hazards. Process controls include written procedures, practices, and processes to ensure the control of parameters during operations. Such controls could include formulation, heat processing, cooling within appropriate timeframes and/or refrigeration. Process controls must include the parameters associated with the control of the hazard, and the minimum or maximum values to which any parameter must be controlled to significantly minimize or prevent the hazards (see 21 CFR 117.135(c)(1)).
An appropriate preventive control would also be subject to preventive control management components, including monitoring, corrective actions, and verification to ensure control of the hazard of bacterial growth and/or toxin formation due to time/temperature abuse for pathogens such as C. botulinum and B. cereus (see 21 CFR 117.140(a)).
We have concerns about time/temperature abuse of this product in your facility. Specifically, your packaged Ho Foon Cut rice noodles are placed into the (b)(4) within (b)(4) of production for (b)(4) at approximately 5:00 PM where the noodles are stored for approximately (b)(4). On March 17, 2026, FDA investigators observed that (b)(4) separate batches of Ho Foon Cut rice noodles manufactured at (b)(4) did not sufficiently cool in the freezer, with product temperatures decreasing from 76°F (24°C) to 62 – 66°F (17–19°C) over approximately 5 hours. Furthermore, you do not monitor the temperature of your refrigerated cooler during storage.
Your use of ROP for finished products is concerning based on the time-temperature abuse observed during our inspection. ROP should not be used unless appropriate barriers to Clostridium botulinum growth and toxin formation are implemented. FDA recommends referencing our Hazard Analysis and Risk-Based Preventive Controls for Human Foods: Draft Guidance for Industry and utilizing Chapter 4: Preventive Controls in the Hazard Analysis and Risk-Based Preventive Controls for Human Foods: Draft Guidance for Industry to identify suitable control measures for growth and toxin formation of Bacillus cereus and Clostridium botulinum. Additionally, Appendix 3, Table 3-A provides limiting conditions for pathogen growth that can be applied to control relevant hazards through product formulation.
B. You did not identify and evaluate the hazard of vegetative bacterial pathogen survival of a lethal treatment as a hazard requiring a preventive control for your RTE Ho Foon Cut rice noodles.
Your facility manufactures RTE Ho Foon Cut rice noodle products by (b)(4) your rice noodles. Vegetative bacterial pathogens have been associated with rice and rice-based noodles. Therefore, vegetative bacterial pathogens are a known or reasonably foreseeable hazard in manufacturing rice noodles.
If the rice noodles are underprocessed, vegetative bacterial pathogens could survive. Therefore, a knowledgeable person manufacturing/processing food in your circumstances would identify pathogen survival of a lethal treatment as a hazard requiring a preventive control.
Your facility has not established preventive controls, such as process controls, for these hazards. Process controls include written procedures, practices, and processes to ensure the control of parameters during operations (b)(4). Process controls must include the parameters associated with the control of the hazard and the minimum and maximum values needed to significantly minimize or prevent the hazards (see 21 CFR 117.135(c)(1)).
An appropriate preventive control would also be subject to preventive control management components, including monitoring, corrective actions, and verification to ensure control of the hazard of vegetative bacterial pathogen survival of a lethal treatment.
We have concerns that you are not eliminating vegetative pathogens in your rice noodles during the (b)(4) process. On March 19, 2026, during production of RTE Ho Foon Cut rice noodles packaged in 2 lb. bags, investigators found that the rice noodle mixture entered the (b)(4) at an internal product temperature of 57°F (14°C) and exited the (b)(4) after 56 seconds at 149°F (65°C).
Furthermore, you have not conducted a validation study demonstrating that your process will adequately destroy vegetative bacterial pathogens (see 21 CFR 117.160.)
C. You did not identify and evaluate recontamination with environmental pathogens as a hazard requiring a preventive control for your RTE Ho Foon Cut rice noodles and tofu products.
Your facility manufactures Ho Foon Cut rice noodle products and tofu, which are RTE and exposed to the environment after cooking and prior to packaging. Therefore, contamination with environmental pathogens is a known or reasonably foreseeable hazard. The packaged foods do not receive any further lethal treatment or otherwise include a control measure that would significantly minimize the pathogen. Therefore, a knowledgeable person manufacturing/processing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control. Preventive controls include sanitation controls, which include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR 117.135(c)(3)).
Although your facility maintains a written sanitation program titled “Equipment Sanitation Doc# EQ-001 Ver. 3.0” with an effective date of 2/1/2025, it does not include: cleaning/sanitation procedures for the tofu line, procedures related to employee practices and hand hygiene, and preventive control management components. Preventive controls are subject to preventive control management components (monitoring, verification, and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR 117.140).
In addition, you did not have adequate controls in place for contamination with environmental pathogens, as evidenced by the following observations during the inspection on March 17 and 18, 2026:
Cleaning and sanitation of equipment
• On March 18, 2026, the production manager stated he had verified the (b)(4) sanitizer concentration (b)(4) prior to use on food-contact surfaces for manufacturing RTE Ho Foon Cut rice noodles. However, investigators observed him measuring the sanitizer concentration at approximately 100 ppm with a test strip. Your production manager did not follow the (b)(4) sanitizer’s instructions for use or your “Equipment Sanitation Doc #: EQ-001” procedure, which specified the sanitizer concentration of (b)(4), and required documentation of the sanitizer strength on “Attachment 4”. Your firm then manufactured rice noodles on this equipment where RTE products came in direct contact on March 19, 2026.
• On March 18, 2026, during post-manufacturing sanitation of RTE Ho Foon Cut rice noodles equipment, investigators observed residual noodles remaining on food-contact surfaces (e.g. (b)(4) on the line (b)(4) conveyor) in (b)(4) areas, after the sanitation crew completed cleaning but before sanitizer application.
Employee practices
• An employee wearing rubber gloves draped a red water hose (a portion of which routinely touched the floor) over the frame of the tofu press, then used a scoop to transfer RTE tofu into drain molds. The scoop, including the handle, was placed inside the RTE tofu in the drain mold. The employee did not wash or sanitize their hands or change their gloves between these activities.
• An employee touched a floor dolly, then a yellow basket holding drain cloths (to be washed), and then picked up a knife to cut RTE tofu into cubes. The employee then picked up the drain tray containing RTE tofu and (b)(4) placed the cubed RTE tofu into the cooling bath. The employee did not wash or sanitize their hands or change their gloves between these activities.
• An employee returned from break and did not wash or sanitize their hands before removing plastic containers and lids (primary packaging) from bags in cardboard boxes and placing them on the table or in a plastic crate. The employee was routinely touching the food-contact surfaces of the containers. These containers and lids were then used for packaging of the silken tofu lot # (b)(4).
• An employee handled a blue floor pallet routinely stored in the firm's cooler (used for holding packaged RTE tofu) and placed it by the tofu packaging table. The employee only rinsed their hands with water (no soap), put on gloves and (b)(4) packaged RTE silken tofu lot (b)(4).
D. You did not identify and evaluate undeclared allergens due to incorrect labeling as a hazard requiring a preventive control. Your Ho Foon Cut Noodles include (b)(4) as an ingredient. Therefore, undeclared allergens due to incorrect labeling is a known or reasonably foreseeable hazard, and a knowledgeable person manufacturing/processing food in your circumstances would identify the hazard as requiring a preventive control at the bagging/labeling step. Preventive controls, such as allergen or process controls, include written procedures, practices, and processes for labeling the finished food to control food allergens, including by ensuring that the finished food is not misbranded under section 403(w) of the Act (see 21 CFR 117.135(c)(2)).
You do not have written allergen control procedures, including monitoring, corrective action and verification to ensure control of the hazard of undeclared allergens due to incorrect labeling.
Your response to the FDA-483 dated April 28, 2026 stated that you have reached out to a new consultant to assist in the development of a Food Safety Plan, that you have scheduled PCQI training, and that you are working on finding ways that will work with your production process and limited freezer space to help cool down the Ho Foon noodles in the appropriate timeframe. You stated that you are also researching companies that provide in-person food safety training in multiple languages for employees. However, to date, you have not provided additional information or other substantive documents to the Agency regarding these issues.
Current Good Manufacturing Practice (21 CFR Part 117, Subpart B)
1. Your plant was not constructed in such a manner so that floors may be adequately cleaned and kept clean and kept in good repair, and that drip condensate from fixtures, ducts and pipes does not contaminate food and food-contact surfaces, as required by 21 CFR 117.20(b)(4). Specifically,
• Condensate was observed on the overhead water pipe directly above the RTE tofu packaging table, and droplets were observed on the food-contact surfaces of the primary packaging including lids and containers used to package Silken Tofu lot #(b)(4).
• Condensate from the water line and on/off valve was dripping directly into the tofu cooling bath. The cooling bath was filled with water, and cubed tofu lot # (b)(4) was placed directly in the water for cooling.
• The floor in the production area where RTE tofu is processed and packaged had missing cement and exposed aggregate.
Your response to the FDA-483 dated April 28, 2026 stated that you have resurfaced and epoxied the floor of the tofu production area, with photographs. Your response did not address drip condensate. We will verify the adequacy of your corrective actions during a future inspection of your facility.
The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.
Please notify FDA in writing within fifteen (15) working days of receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.
Please send your reply to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Elodie Tong-Lin, Compliance Officer at elodie.tong-lin@fda.hhs.gov. If you have any questions regarding this letter, you may contact Elodie Tong-Lin, Compliance Officer, via email at elodie.tong-lin@fda.hhs.gov. Please include reference CMS #730984 on any submissions and within the subject line of any email correspondence to the agency.
Sincerely,
/s/
Maria S. Knirk, JD MBA
Director
Office of Enforcement
Office of Compliance and Enforcement
Human Foods Program
出典: fda.gov(U.S. FDA)の Warning Letters 公開情報 (米国政府著作物としてパブリックドメイン)をそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。
Warning Letter の最新状態・Close-out(是正完了)の正は FDA 公式サイトです。是正が完了した企業には Close-out Letter が発行される場合があり、本サイトの表示が最新の状態を反映していないことがあります。掲載は事実の転載であり、企業の現在の法令遵守状況について評価・断定するものではありません。
取得日: 2026.11.17
各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。